ALTHE — Theraclion SA Share News
0.000.00%
Last trade - 00:00- €41.86m
- €43.43m
- €1.19m
Brief: theraclion's echopulse covered by french national health insurance for the treatment of breast fibroadenomas
Brief: Theraclion H1 revenue eur 561,000
Brief: Theraclion announces FDA authorization to start US trial for immunotherapy and echotherapy combination on breast cancer
Brief: Theraclion and Inner Mongolia Furui Medical Science Co. sign joint venture in China
Brief: Theraclion reports positive long-term Echopulse results in breast fibroadenoma
Brief: Theraclion FY net loss stable at 6.8 million euros
Brief: Theraclion announces first patients treated in U.S. Pivotal Multicentre FDA study
Brief: Theraclion 2016 sales of 1.9 million euros, up 8 pct
Brief: Theraclion signs two commercial agreements in Frankfurt for Echopulse systems
Brief: Theraclion announces major french hospital group now offers echotherapy for treatment of thyroid nodules
Brief: First acquisition of Theraclion's Echopulse in Switzerland
Brief: Theraclion announces installation of echotherapy system in UK
Brief: Theraclion H1 net loss widens to 3.5 million
Brief: AOK Bremen/Bremerhaven starts reimbursement coverage of Theraclion's echotherapy
Brief: First data generated in US Support Theraclion's echotherapy system
Brief: Theraclion launches 9.63 million euro capital increase
Brief: Theraclion H1 revenue jumps 1,119 pct to 463,000 euros
Brief: Theraclion announces that a hospital based Italy has signed a commercial agreement for use of Echopulse system
Brief: Theraclion signs commercial agreement with Klinikum Stephansplatz-Hamburg